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Abstract
For the exceptional self-renewal capacity, regulated cell proliferation and differential potential to a
wide variety of cell types, the stem cells must maintain the intact genome. The cells under
continuous exogenous and endogenous genotoxic stress accumulate DNA errors, drive
proliferative expansion and transform into cancer stem cells with a heterogeneous population of
tumor cells. These cells are a common phenomenon for the hematological malignancies and solid
tumors. In response to DNA damage, the complex cellular mechanisms including cell cycle arrest,
transcription induction and DNA repair are activated. The cells when exposed to cytotoxic agents,
the apoptosis lead to cell death. However, the absence of repair machinery makes the cells
resistant to tumor sensitizing agents and result in malignant transformation. Mismatch repair gene
defects are recently identified in hematopoietic malignancies, leukemia and lymphoma cell lines.
This review emphasizes the importance of MMR systems in maintaining the stem cell functioning
and its therapeutic implications in the eradication of cancer stem cells and differentiated tumor cells
as well. The understanding of the biological functions of mismatch repair in the stem cells and its
malignant counterparts could help in developing an effective novel therapies leaving residual non-
tumorigenic population of cells resulting in potential cancer cures.
Background
Gurdon first introduced the concept of stemness state of
the cells while successfully achieving the generation of all
cell lineages of a living tadpole after transferring the nuclei
from intestinal epithelial cells of feeding Xenopus tad-
poles to activated enucleated eggs [1,2]. These types of
cells were later on characterized as indispensable entities,
identified in multicellular organisms. The stem cell phe-
notype is contributed by the unique features that include
(1) self-renewal which means that after cell division, one
of the daughter cells must have the same genetic material
as that of the parent cell, (2) differentiation i.e. capability
to differentiate into multiple lineages and (3) extensive
proliferation. The adult stem cells are identified in variety
of tissues and organs in humans including – bone mar-
row, brain, skin/hair follicles, heart, lung, intestine, liver,
pancreas, mammary glands, ovaries, prostrate, and testis
[3].
The multipotency of stem cells to maintain tissue home-
ostasis and its differentiation into mature cell types is
under a tightly controlled system and is associated with
restricted expression profile. The expression of transport
proteins – ABC (ATP-binding cassette) transporter pro-
teins and multidrug resistant proteins that protect cells
against toxins and are associated with the efflux of xeno-
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biotic toxins, low rate of cell division and active DNA
repair are the innate properties of normal development of
stem cells. Besides hormonal stimulation, DNA damage is
one of the key factors for stem cell activation. DNA accu-
mulates errors either from environmental factors, which
could be the exposure to radiation, chemicals or drugs,
viruses and bacteria or DNA replication errors [4]. This
would result in complex cellular responses that include
loss of cell cycle regulation, transcription induction and
DNA repair mechanisms for maintaining genomic and
chromosomal stability. But in absence of efficient DNA
repair machinery, the stem cells accumulate harmful
mutations and become resistant to apoptosis resulting in
the loss of genome or instability, which ultimately lead to
malignant transformation of stem cells [5]. Table 1 fea-
tures the stem cell activation types, which transforms
them into different cancer types [4,6]. Each stem cell acti-
vation type is exemplified with a single cancer type in the
Table 1, however many could be associated. The progeni-
tor cells also known as transit – amplifying cells arise from
normal stem cells have replicative ability but not self-
renewal capacity. Mutations in these progenitor cells help
in regaining self-renewal property and become cancerous
(Fig 1).
Cancer stem cells (CSCs) were first identified in 1990s in
hematological malignancies, mainly acute myelogenous
leukemia (AML) and also in other subtypes like AML M0,
M1, M2, M4 and M5 and chronic myeloid leukemia
(CML), acute lymphoblastic leukemia (ALL) and multiple
myeloma [7]. CSCs are also known in solid tumors like
breast, brain, lung, prostrate, testis, ovary, stomach, colon,
skin, liver, pancreas [8-10]. These tumor cells have a self-
renewal property but undergo aberrant differentiation
and constitute the heterogeneous population of tumor
cells [11].
In the hematopoietic and solid tumors side population
(SP) containing CSCs constitute the fraction of total pop-
ulation of cells that shows that CSCs is a common phe-
nomenon for all the malignancies. SP can be identified by
the efflux of fluorescent dyes by ABC transporter proteins
which are the major multidrug resistant genes. In the
absence of DNA repair capacity, the drug resistant pluor-
ipotent cells accumulate mutations and show increased
cell survival [12].
DNA repair
To maintain the genomic integrity and normal function-
ing of stem cells, several DNA repair pathways come into
interplay and provide the robust defense to the cell.
Absence of these repair processes have a great impact on
the diminution of stem cells and increased chance for
Table 1: Stem cell activation types transforming normal stem cells into cancerous stem cells
Stem cell activation type Target tissue/organ Cancer type
Naturally activated stem cell: Inactivation of RB1 gene Retinoblasts Retinoblastoma
Loss of tumor suppressor genes (p53) Breast Breast
Expression of oncogenes (ras, myc) Brain Brain
Hormonal stimulation: estrogen Breast Breast
Inflammation: Crohn disease, inflammatory bowl disease, result in activated cell growth Colon Colon
Viral infection: Hepatitis B and C cause inflammation and extensive cirrhosis Liver Liver
Exposure to irritants like tobacco, asbestos cause inflammation Lung Lung
Bacterial infection: Helicobacter pylori and metal dust exposure cause inflammation Stomach Stomach
Loss of miRNA genes (miR15 and miR16) which act as tumor suppressors Bone marrow Chronic lymphoid leukemia
Enforced expression of miR17-92 cluster which acts as oncogenes Bone marrow B cell lymphoma
DNA methylation at 5-position at cytosine residue within CpGs by Dnmt1 (maintenance 
methyltranferase), Dnmt3a, 3b (initiate de novo methylation), Dnmt2
Colon Colorectal
Methylation dependent repression of transcription by binding of methyl CpG binding proteins- 
MECP2, MBD1-4, Kaiso to DNA
Colon Colorectal
Histone methylation by H3K4 Mtases, H3K9 Mtases, Suv39h1/Suv39h2, G9a, Eu-H Matse1, 
ESET/SETDB1
Prostate Prostate
Histone acetylation via histone acetyltransferases (HAT) include Gcn5 family proteins, MYST 
protein, p300/CBP, TAF250, ACTR/SRC1 nuclear receptor cofactors mediate transcriptional 
activation
Breast Breast
Histone deacetylation silences gene expression via HDAC I family, HDAC II family, Sirtuin 
family (Sir2) 
Bone marrow Acute myeloid leukemia
Blockage of DNA accessibility to transcription factors by polycomb group proteins which 
include Polycomb repressive complexes – PRC1 contains Cbx, Mph, Ring, Bmi-1, Mel18 and 
PRC2 contains Ezh2, Suz12 and Eed
Bone marrow B and T cell lymphoma
Alteration in chromatin accessibility to proteins and restriction endonucleases by the 
disruption of association of histones with DNA using the energy by ATP hydrolysis via ATP 
dependent remodeling complexes (SWI2/SNF2 protein, ISWI enzymes, Mi-2/NuRD proteins
Bone marrow Acute myeloid leukemiaMolecular Cancer 2007, 6:26 http://www.molecular-cancer.com/content/6/1/26
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stem cell differentiation and malignant transformation
due to altered gene expression.
(a) O6- alkylguanine DNA alkyl transferase (AGT) repair
AGT repair is a DNA repair protein encoded by MGMT
(O6-methylguanine DNA methyltransferase) removes
DNA adducts from O6 methylguanine. The failure in the
repair system results in G to A transition and DNA strand
break observed in hematopoietic tumors, breast, ovarian
and retinoblastomas [13,14].
(b) Nucleotide Excision Repair (NER)
In NER, the damaged DNA bases are recognized by XPC
(xeroderma pigmentosum complementation group C)
and RAD23B whereas XPA, RPA (replication protein A),
RNA polymerase II transcription factor 11A and XPG
excise the fragment of 27–30 nucleotides surrounding the
damaged bases. The gap is further restored by DNA
polymerases and ligases and replaces it with the correct
sequence. Defective NER leads to xeroderma pigmento-
sum (skin cancer) [15].
(c) Base Excision Repair (BER)
It comprises of short and long patch pathways where DNA
glycosylases generate apurinic/apyrimidinic (AP) fol-
lowed by its 5' excision by AP endonucleases (APE-1) and
remove damaged bases. Double-stranded breaks have the
potential to be the most disruptive form of DNA damage
[16,17].
(d) Non-Homologous DNA End-Joining (NHEJ) repair
Double-stranded breaks have the potential to be the most
disruptive form of DNA damage. The DNA double strand
breaks (DSBs) produced by free radicals generated during
Development of cancer stem cells from the normal stem cells and progenitor cells Figure 1
Development of cancer stem cells from the normal stem cells and progenitor cells. Accumulation of DNA errors in normal 
stem cells or progenitor cells are activated to generate a cancer stem cells (CSCs) that further generate a primary tumor con-
stituting CSCs and other tumor cells.


















Differentiated primary tumorMolecular Cancer 2007, 6:26 http://www.molecular-cancer.com/content/6/1/26
Page 4 of 8
(page number not for citation purposes)
oxidative respiration, ionizing radiation, DNA replica-
tion, malfunction of recombination activating gene com-
plex during V(D)J (variable region, diversity region-
junction region) recombination in T and B lymphocytes
are brought in closed proximity by Ku70-Ku80 het-
erodimer and kinase activity by DNA dependent protein
kinase catalytic subunit (DNA-PKcs) of DNA-PK complex
followed by its ligation by XRCC4-DNA ligase IV, SCID
(Severe Combined Immunodeficiency) is associated with
defective NHEJ repair system [15].
(e) Homologous Recombination (HR) repair
The DSBs are repaired by misalignment, deletions, and
rearrangement. ATM, a PI-3 Kinase binds DNA and phos-
phorylates multiple proteins. BRCA1 activated by ATM
(ataxia telangiectasia) facilitates BRCA2 and RAD51 bind-
ing of the overhang followed by the attraction of RAD52/
RAD54 with the help of BLM/WRN proteins. The homol-
ogous recombination is facilitated by large protein com-
plexes at the DSBs. High incidence of leukemia, breast-
ovarian, Werner's and Bloom's syndrome with severe pre-
mature aging and cancer is seen in defective HR repair sys-
tem [18,19].
(f) Mismatch Repair (MMR)
It is a genome surveillance system in bacteria, yeast and
mammals by maintaining genomic integrity. The MMR
pathway is the form of DNA repair responsible for the
elimination of specific mismatched and/or unmatched
bases and insertion-deletion loops (IDLs) where DNA
synthesis is liable to errors, either as a part of DNA repli-
cation before cell division, or as part of DNA repair
(unscheduled DNA synthesis) [20]. Although DNA
polymerases have the ability to identify and correct their
own errors, some mistakes are not identified.
Mismatch in eukaryotic DNA is recognized by two het-
erodimeric complexes of Mut S related proteins – MSH2/
GTBP (Mut Sα) and MSH2/MSH3 (Mut Sβ) [21]. Mut Sα
binds to both base – base mismatches and small ID (inser-
tion – deletion) heterologies whereas Mut Sβ plays major
role in repair of larger ID mispairs [22]. Presence of ATP
markedly decreases the affinity of Mut Sα for an oligonu-
cleotide heteroduplex, an effect also observed with bacte-
rial Mut S. Hydrolysis of ATP facilitates protein – protein
interactions and or sliding along with DNA [23]. Recogni-
tion of mispair is followed by binding of Mut Sα (MSH2/
MSH3) with Mut L related proteins [MLH1/hPMS2
(PMS1 in yeast)] and converts into high molecular weight
structure. It also increases the efficiency of Mut S proteins
to recognize the mismatch. MLH1/MLH3 (PMS2 in
humans) also forms the complex with Mut Sβ and help in
repair of ID mispairs [24].
Proliferating cell nuclear antigen (PCNA) has been identi-
fied as DNA polymerase processivity factor and has a role
in repair at or prior to excision steps as a strand discrimi-
nating factor [25]. Bi – directional threading of DNA
through hMut S heterodimer is continued till the arrest of
forward movement of replication fork that occurs via an
interaction with PCNA in the polymerase complex.
Recently another eukaryotic mismatch repair endonucle-
ase has been identified whose amino terminal domain is
involved in binding to fully methylated DNA and car-
boxyl terminal region is involved in catalysis and complex
formation with Mut L homologue MLH1. This protein is
named as MED1 (methyl – CpG binding endonuclease 1).
The properties of MED1 felicitate it to be a functional
homologue of MutH [26].
DNA exonuclease and helicase unwind, nick and degrade
the error – containing strand. After dissociation of MMR
complex, PCNA, which still binds at the end of error con-
taining primer strand, recruits replication complex and
thus re-initiation starts with the help of DNA polymerase.
The mutations characterized by point mutations, inser-
tions or deletions in the length of DNA microsatellite
repeat sequences throughout the genome resulting in mic-
rosatellite instability (MSI) is a hallmark of defective DNA
MMR system which result in malignant transformation
[27].
The maintenance of MMR system decreases the error rates
by 100 to 1000 fold during DNA replication. Since it has
tremendous importance in the carcinogenesis, this review
presents a discussion on the role of DNA mismatch repair
system as a therapeutic potential in eliminating the cancer
stem cells.
MMR deficiency and stem cell defects
The maintenance and longevity of stem cell phenotype is
characterized by the presence of efficient MMR system,
which result in accurate DNA replication, restore normal
DNA after its damage and remove replication defects at
microsatellite sequences by repairing the DNA polymer-
ase slippage products.
The MMR deficiencies because of the mutations in wild
type MMR allele with Msh2-/- and Mlh2-/- phenotype, mice
develop stem cell-derived-lymphoid malignancies and all
lymphoid tumors show MSI [28]. The serial bone marrow
transplantation assay was done to compare Msh2-/- pri-
mary murine hematopoietic cells with wild type into
lethally irradiated mice with temozolomide, a methylat-
ing agent. MMR deficiency as evident by MSI was observed
in early progenitor colony forming unit (CFU) and
Sca+Kit+Lin- derived clones, which explain the alteration
in growth and survival of hematopoietic stem cells and itsMolecular Cancer 2007, 6:26 http://www.molecular-cancer.com/content/6/1/26
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long-term repopulation capacity because of accumulation
of genomic instability [5]. In another study, colonogenic
survival was assayed in Msh2-/-, Msh2+/+, Msh2-/+ mouse
embryonic stem cells following prolonged low level radi-
ation treatment. The cells deficient in active MMR system
survive promutagenic genomic insults by alkylating and
oxidating agents that contribute to neoplastic transforma-
tion as in hereditary non-polyposis colorectal cancer
(HNPCC) [29]. The six cases of childhood leukemia are
reported where patients are homozygous for MSH2,
MLH1 or PMS2 loss of function mutations [30].
The loss of MMR genes directly or indirectly alters signal
pathways, loss of strictly regulated expression of cytokine
receptors, transcription factors and cell cycle regulation
[5]. Unlike normal stem cells the presence of damaged
DNA does not activate p53 induced G1 cell cycle arrest
and also the repair helicases XPB and XPD fail to function-
ally interact with p53 [31,32]. This contributes to the loss
of stem cell phenotype, a proliferative advantage and can-
cer stem cell formation.
The mitotic homologous recombination can result in
chromosomal translocations, deletions or inversions with
deleterious consequences in the adult or during develop-
ment. Loss of MMR adds up an additional level of genetic
instability in a form of chromosomal rearrangements
commonly observed in hematological malignancies. High
incidence of lymphoma is reported in Msh2 deficient
mouse embryonic stem cells [33].
The Msh2 low and deficient mouse ES cells showed poor
or complete elimination of repair function and demon-
strated the resistance against the toxic effects of an ethylat-
ing agent, N-ethyl-N-nitrosourea (ENU). The ENU-
induced mutagenicity under the fully or partially deficient
conditions accelerated the lymphomagenesis [34]. Toft et
al., showed the increase in mutation frequency at Dlb-1
locus due to loss of Msh2 status in normal intestinal cells
predispose to malignancy. The increased colonogenicity
was observed in Msh2-/- mouse ES cells after exposure to
temozolomide but not cisplatin and contributed to failed
repair mechanism and apoptosis in a p53 dependent
manner [35].
In a study by Fink et al., Msh2-/- mouse embryonic stem
cells showed two-fold resistance to the cytotoxic effects of
cisplatin as compared to wild type cells [36]. On the con-
trary, Claij & Riele found no relation between the MMR
capacity of cells and their response to cisplatin in a colo-
nogenic assay in mouse ES cells [37]. However, certain
specific changes like mutated p53 [38], increased recom-
binational repair or increased replicative bypass are col-
laborated with MMR deficiency in affecting the
cytotoxicity of cisplatin.
Therapeutic implications of mismatch repair in cancer 
stem cells
In most of the malignancies CSCs constitute less than 1%
of total cell population. They are in quiescent state and
most of the conventional chemotherapeutic drug thera-
pies are effective in actively dividing cells, so for complete
eradication of CSCs, the therapeutic agents either should
kill cells independently of the cell cycle or selectively
induce cycling of cancer cells. Moreover, therapy should
target pathways uniquely used by CSCs. CSCs express var-
ious drug transporter proteins which efflux the cytotoxic
drugs and protect them from damage. The inhibitors to
these transporters make the CSCs sensitive to chemother-
apy. Since normal stem cells also express some of these
transporters so non selective inhibition of these multidrug
resistant genes also kill normal stem cells. The characteri-
zation of stem cells markers would help in identification
of CSCs from normal stem cells have important implica-
tions in elimination of CSCs by specifically targeting the
tumor cells [39]. Table 2 lists the human cell surface mark-
ers in normal as well as CSCs, which are used to distin-
guish the two populations of cells.
The wild type MMR expression blocks the homologous
recombination between the diverged DNA sequences
throughout the genome and thus prevent the stem cell to
accumulate further genetic instability. Hematological
malignancies and lymphoma arise due to chromosomal
rearrangements because of loss of MMR proteins [33]. The
efficient mismatch repair mechanisms engage the stem
cells to undergo apoptosis when DNA is damaged. For
example, hematopoietic stem cells show premature senes-
cence (cellular aging) when they are exposed to ionizing
Table 2: Markers expressed in normal and cancer stem cells in humans
Organ Cancer type Normal stem cell markers Cancer stem cell markers References
Hematopoietic Leukemia CD34+CD38-Thy1-Lin- CD34+CD38- Thy1-Lin- [47, 48]
Breast Mammary cancer CD24med CD44+CD24-/lowESA+Lin- [8, 11]
Brain Brain tumor CD133+Lin- CD133+ Nestin [49, 50]
Skin Melanoma cancer CD20-CD166- Nestin- CD20+ CD166+ Nestin+ [51, 52]
Prostate Prostate cancer CD133+α2β1
hi CD44+α2β1
hiCD133+ [53]
Tongue, Larynx, Throat and Sinus Head and neck squamous cell carcinoma (HNSCC) CD44- CD44+ [54]
Pancreas Pancreatic cancer CD24-CD44-ESA- CD24+ CD44+ESA+ [48]Molecular Cancer 2007, 6:26 http://www.molecular-cancer.com/content/6/1/26
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radiation or busulfan [40]. In response to alkylation or
oxidative DNA damage, the DNA MMR machinery
directly or indirectly stimulates signal transduction, tran-
scription factors, loss of cell cycle regulation that derive
cell fate decision pathways including apoptosis. The cells
with damaged DNA bases undergo G2 arrest in presence
of hMLH1 as well as the checkpoint kinases ATR and
Chk1 [41]. The stress kinase p38 is activated in presence
of hMLH1 and its inhibition cause cells to bypass G2
arrest [42]. Cisplatin treated cells redistribute hPMS2 to
the nucleus and its functional interaction with p73, a p53
related protein increases cell death [43]. Functional
hMSH2 and hMLH1 also activates c-Abl, one of the pro-
teins of p73 dependent apoptosis pathway [44,45]. The
MMR proteins allow the cisplatin-induced initiation of
G1 arrest by cyclin D1 degradation [46]. Defective MMR
along with the mutated p53 response contributes to cispl-
atin resistance [38].
Most of the human cancers are identified having mis-
match repair deficiency that result in defect in cell cycle
and altered growth as in case of hematological malignan-
cies. The defective MMR status in a damaged cell directly
contributes to the resistant phenotype against the cyto-
toxic effects of chemotherapeutic drugs and thus these
CSCs survive chemotherapy (Fig 2). The activation of
DNA MMR system would help in inhibiting the survival
mechanisms by raising the sensitivity of such cells to ther-
apeutic drugs and reduce its tumor potential by arresting
their growth. Owning to mass effect, progeny cancer cells
still show the symptoms in the patients and therefore, the
combinational therapy for the eradication of cancer stem
cells and differentiated cells would be more effective.
Antitumor treatment strategies selectively targeting the
subset of tumor stem cells would be of clinical signifi-
cance.
Conclusion
The maintenance of genomic stability is the prime
requirement for the stem cell phenotype and its normal
functioning. The increased mutation rate and absence of
MMR may give rise to stem cell failure, a proliferative
advantage and cancer stem cells formation. The cancer
stem cells having MMR deficiencies make them insensi-
tive to the treatments against the cytotoxic agents and
would increase the risk of relapse and metastasis. The
Active mismatch repair system in primary tumors help in the induction of cell death after chemotherapy Figure 2
Active mismatch repair system in primary tumors help in the induction of cell death after chemotherapy. Primary tumors con-
taining heterogeneous population of tumor cells along with small % of cancer stem cells (CSCs, represented by dark gray 
colored oval shape undergo chemotherapy. Presence of active mismatch repair induces cellular response followed by apopto-
sis, which lead to cell death. However, mismatch repair deficiency makes tumor cells insensitive to drug and it relapses.
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importance of MMR in designing the therapeutic strate-
gies specifically targeting the tumor cells is being explored
and pursued in the clinical trials.
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